ARWR
Price
$16.08
Change
+$0.01 (+0.06%)
Updated
Jun 27 closing price
Capitalization
2.22B
43 days until earnings call
PGEN
Price
$1.42
Change
-$0.01 (-0.70%)
Updated
Jun 27 closing price
Capitalization
419.16M
43 days until earnings call
Interact to see
Advertisement

ARWR vs PGEN

Header iconARWR vs PGEN Comparison
Open Charts ARWR vs PGENBanner chart's image
Arrowhead Pharmaceuticals
Price$16.08
Change+$0.01 (+0.06%)
Volume$2.08M
Capitalization2.22B
Precigen
Price$1.42
Change-$0.01 (-0.70%)
Volume$5.16M
Capitalization419.16M
ARWR vs PGEN Comparison Chart in %
Loading...
ARWR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PGEN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ARWR vs. PGEN commentary
Jun 29, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ARWR is a Buy and PGEN is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 29, 2025
Stock price -- (ARWR: $16.08 vs. PGEN: $1.42)
Brand notoriety: ARWR: Notable vs. PGEN: Not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ARWR: 129% vs. PGEN: 308%
Market capitalization -- ARWR: $2.22B vs. PGEN: $419.16M
ARWR [@Biotechnology] is valued at $2.22B. PGEN’s [@Biotechnology] market capitalization is $419.16M. The market cap for tickers in the [@Biotechnology] industry ranges from $299.85B to $0. The average market capitalization across the [@Biotechnology] industry is $2.3B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ARWR’s FA Score shows that 1 FA rating(s) are green whilePGEN’s FA Score has 0 green FA rating(s).

  • ARWR’s FA Score: 1 green, 4 red.
  • PGEN’s FA Score: 0 green, 5 red.
According to our system of comparison, ARWR is a better buy in the long-term than PGEN.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ARWR’s TA Score shows that 3 TA indicator(s) are bullish while PGEN’s TA Score has 3 bullish TA indicator(s).

  • ARWR’s TA Score: 3 bullish, 4 bearish.
  • PGEN’s TA Score: 3 bullish, 5 bearish.
According to our system of comparison, ARWR is a better buy in the short-term than PGEN.

Price Growth

ARWR (@Biotechnology) experienced а +4.96% price change this week, while PGEN (@Biotechnology) price change was -2.07% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.13%. For the same industry, the average monthly price growth was +31.22%, and the average quarterly price growth was +12.91%.

Reported Earning Dates

ARWR is expected to report earnings on Aug 11, 2025.

PGEN is expected to report earnings on Aug 11, 2025.

Industries' Descriptions

@Biotechnology (+4.13% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ARWR($2.22B) has a higher market cap than PGEN($419M). PGEN YTD gains are higher at: 26.786 vs. ARWR (-14.468). ARWR has higher annual earnings (EBITDA): -68.12M vs. PGEN (-154.85M). ARWR has more cash in the bank: 1.1B vs. PGEN (80.2M). PGEN has less debt than ARWR: PGEN (5.42M) vs ARWR (388M). ARWR has higher revenues than PGEN: ARWR (545M) vs PGEN (4.2M).
ARWRPGENARWR / PGEN
Capitalization2.22B419M530%
EBITDA-68.12M-154.85M44%
Gain YTD-14.46826.786-54%
P/E RatioN/AN/A-
Revenue545M4.2M12,973%
Total Cash1.1B80.2M1,368%
Total Debt388M5.42M7,163%
FUNDAMENTALS RATINGS
ARWR vs PGEN: Fundamental Ratings
ARWR
PGEN
OUTLOOK RATING
1..100
7628
VALUATION
overvalued / fair valued / undervalued
1..100
94
Overvalued
70
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
96100
PRICE GROWTH RATING
1..100
5943
P/E GROWTH RATING
1..100
2100
SEASONALITY SCORE
1..100
8530

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

PGEN's Valuation (70) in the null industry is in the same range as ARWR (94) in the Biotechnology industry. This means that PGEN’s stock grew similarly to ARWR’s over the last 12 months.

PGEN's Profit vs Risk Rating (100) in the null industry is in the same range as ARWR (100) in the Biotechnology industry. This means that PGEN’s stock grew similarly to ARWR’s over the last 12 months.

ARWR's SMR Rating (96) in the Biotechnology industry is in the same range as PGEN (100) in the null industry. This means that ARWR’s stock grew similarly to PGEN’s over the last 12 months.

PGEN's Price Growth Rating (43) in the null industry is in the same range as ARWR (59) in the Biotechnology industry. This means that PGEN’s stock grew similarly to ARWR’s over the last 12 months.

ARWR's P/E Growth Rating (2) in the Biotechnology industry is significantly better than the same rating for PGEN (100) in the null industry. This means that ARWR’s stock grew significantly faster than PGEN’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ARWRPGEN
RSI
ODDS (%)
Bearish Trend 3 days ago
86%
N/A
Stochastic
ODDS (%)
Bullish Trend 3 days ago
72%
Bullish Trend 3 days ago
79%
Momentum
ODDS (%)
Bearish Trend 3 days ago
87%
Bearish Trend 3 days ago
89%
MACD
ODDS (%)
Bearish Trend 3 days ago
84%
Bearish Trend 3 days ago
85%
TrendWeek
ODDS (%)
Bullish Trend 3 days ago
76%
Bearish Trend 3 days ago
88%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
74%
Bullish Trend 3 days ago
84%
Advances
ODDS (%)
Bullish Trend 3 days ago
81%
N/A
Declines
ODDS (%)
Bearish Trend 13 days ago
83%
Bearish Trend 3 days ago
85%
BollingerBands
ODDS (%)
N/A
Bearish Trend 3 days ago
86%
Aroon
ODDS (%)
Bullish Trend 3 days ago
72%
Bullish Trend 3 days ago
88%
View a ticker or compare two or three
Interact to see
Advertisement
ARWR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PGEN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
CVACX17.970.14
+0.79%
Calamos Select Fund C
RGLGX26.360.19
+0.73%
American Funds Global Insight R-6
RMQAX563.433.93
+0.70%
Rydex Monthly Rbl NASDAQ-100® 2x Strt A
MGOTX8.500.03
+0.35%
Victory Munder Mid-Cap Core Growth C
CSGZX78.180.19
+0.24%
Columbia Seligman Global Tech Inst

ARWR and

Correlation & Price change

A.I.dvisor indicates that over the last year, ARWR has been loosely correlated with DNLI. These tickers have moved in lockstep 58% of the time. This A.I.-generated data suggests there is some statistical probability that if ARWR jumps, then DNLI could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ARWR
1D Price
Change %
ARWR100%
+0.06%
DNLI - ARWR
58%
Loosely correlated
-2.69%
IMNM - ARWR
55%
Loosely correlated
-0.23%
BEAM - ARWR
54%
Loosely correlated
-1.98%
RGNX - ARWR
53%
Loosely correlated
-4.11%
YMAB - ARWR
52%
Loosely correlated
-2.08%
More

PGEN and

Correlation & Price change

A.I.dvisor indicates that over the last year, PGEN has been loosely correlated with ARCT. These tickers have moved in lockstep 47% of the time. This A.I.-generated data suggests there is some statistical probability that if PGEN jumps, then ARCT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PGEN
1D Price
Change %
PGEN100%
-0.70%
ARCT - PGEN
47%
Loosely correlated
-7.49%
TRDA - PGEN
45%
Loosely correlated
-1.57%
ARWR - PGEN
45%
Loosely correlated
+0.06%
CRSP - PGEN
45%
Loosely correlated
N/A
XENE - PGEN
44%
Loosely correlated
+0.62%
More